Cargando…
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
To achieve synergistic therapeutic efficacy and prevent cancer relapse, chemotherapy and immunotherapy have been combined as a new modality for tumor treatment. In this work, we designed a redox-responsive immunostimulatory polymeric prodrug carrier, PSSN10, for programmable co-delivery of an immune...
Autores principales: | Sun, Jing-jing, Chen, Yi-chao, Huang, Yi-xian, Zhao, Wen-chen, Liu, Yan-hua, Venkataramanan, Raman, Lu, Bin-feng, Li, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520195/ https://www.ncbi.nlm.nih.gov/pubmed/28504251 http://dx.doi.org/10.1038/aps.2017.44 |
Ejemplares similares
-
A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors
por: Nayak, Asha, et al.
Publicado: (2014) -
Immunostimulatory effects on B cells by the chemotherapeutic drug Doxorubicin
por: Kinn, Johan M, et al.
Publicado: (2011) -
Neuroligins Nlg2 and Nlg4 Affect Social Behavior in Drosophila melanogaster
por: Corthals, Kristina, et al.
Publicado: (2017) -
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model
por: Meng, Xiangjing, et al.
Publicado: (2017) -
Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
por: Li, Fu, et al.
Publicado: (2019)